Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside.

Stohl W, Scholz JL, Cancro MP.

Curr Opin Rheumatol. 2011 May;23(3):305-10. doi: 10.1097/BOR.0b013e328344c15e. Review.

2.

Targeting the BLyS-APRIL signaling pathway in SLE.

La Cava A.

Clin Immunol. 2013 Sep;148(3):322-7. doi: 10.1016/j.clim.2012.11.010. Epub 2012 Dec 6. Review.

PMID:
23269199
3.

[Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].

Terrier B, Mouthon L.

Med Sci (Paris). 2013 Jan;29(1):65-73. doi: 10.1051/medsci/2013291015. Epub 2013 Jan 25. Review. French.

4.

Targeting BLyS in systemic lupus erythematosus.

Liu Y, La Cava A.

Recent Pat Inflamm Allergy Drug Discov. 2012 May;6(2):91-6. Review.

PMID:
22216778
5.

Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.

Espinosa G, Cervera R.

Drugs Today (Barc). 2010 Dec;46(12):891-9. doi: 10.1358/dot.2010.46.12.1544336. Review.

PMID:
21589946
6.

The role of B lymphocyte stimulator in B cell biology: implications for the treatment of lupus.

Scholz JL, Oropallo MA, Sindhava V, Goenka R, Cancro MP.

Lupus. 2013 Apr;22(4):350-60. doi: 10.1177/0961203312469453. Review.

PMID:
23553778
7.

Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.

Dennis GJ.

Clin Pharmacol Ther. 2012 Jan;91(1):143-9. doi: 10.1038/clpt.2011.290. Epub 2011 Nov 30. Review.

PMID:
22130121
8.

Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.

Mosak J, Furie R.

Lupus. 2013 Apr;22(4):361-71. doi: 10.1177/0961203312471575. Review.

PMID:
23553779
9.

BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.

Fairfax K, Mackay IR, Mackay F.

IUBMB Life. 2012 Jul;64(7):595-602. doi: 10.1002/iub.1046. Epub 2012 May 29. Review.

10.

B cells as therapeutic targets for rheumatic diseases.

Looney RJ, Anolik J, Sanz I.

Curr Opin Rheumatol. 2004 May;16(3):180-5. Review.

PMID:
15103242
11.

Belimumab for the treatment of systemic lupus erythematosus.

Jordan N, D'Cruz DP.

Expert Rev Clin Immunol. 2015 Feb;11(2):195-204. doi: 10.1586/1744666X.2015.996550. Epub 2014 Dec 29. Review.

PMID:
25543845
12.

Anticytokine therapy impacting on B cells in autoimmune diseases.

Daridon C, Burmester GR, Dörner T.

Curr Opin Rheumatol. 2009 May;21(3):205-10. doi: 10.1097/BOR.0b013e32832a0760. Review.

PMID:
19346949
13.
14.

Belimumab therapy in systemic lupus erythematosus.

Zouali M, Uy EA.

BioDrugs. 2013 Jun;27(3):225-35. doi: 10.1007/s40259-013-0031-8. Review.

PMID:
23568179
15.

Therapeutic targeting of B lymphocyte stimulator (BLyS) in the rheumatic diseases.

Stohl W.

Endocr Metab Immune Disord Drug Targets. 2006 Dec;6(4):351-8. Review.

PMID:
17214581
16.
17.

BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus.

Vincent FB, Morand EF, Mackay F.

Immunol Cell Biol. 2012 Mar;90(3):293-303. doi: 10.1038/icb.2011.111. Epub 2012 Jan 10. Review.

PMID:
22231653
18.

The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity.

Vincent FB, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F.

Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15. doi: 10.1016/j.cytogfr.2013.04.003. Epub 2013 May 15. Review.

PMID:
23684423
19.

Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.

Wiglesworth AK, Ennis KM, Kockler DR.

Ann Pharmacother. 2010 Dec;44(12):1955-61. doi: 10.1345/aph.1P360. Epub 2010 Nov 16. Review.

PMID:
21081710
20.

The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.

Cancro MP, D'Cruz DP, Khamashta MA.

J Clin Invest. 2009 May;119(5):1066-73. doi: 10.1172/JCI38010. Epub 2009 May 1. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk